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Abstract 
Background: To determine the diagnostic accuracy 
of combined serum HBV DNA and serum ALT 
levels for significant liver fibrosis in chronic 
Hepatitis B patients. 
Methods: In this  cross sectional study confirmed 
cases of Hepatitis B were enrolled. Inclusion criteria 
was age more than 20 and both genders, while those 
cases who had history of Hep C or were on treatment 
of Hep B were excluded. Patients’samples were 
taken for HBV DNA and ALT to predict the presence 
of liver fibrosis.  
Results: Out of total 130 cases, there were 72 
(54.5%) males with a mean age of 43.78± 10.28 years. 
The results of HBV DNA + ALT showed 51 (38.6%) 
patients to have fibrosis, whereas endoscopic 
diagnosis of esophageal varices was confirmed in 40 
(30.3%) patients.Sensitivity of HBV DNA + ALT for 
diagnosis of fibrosis was found to be 55%, specificity 
66.6%and diagnostic accuracy 65%. 
Conclusion: Combined HBV DNA & ALT values 
can be advised as predictor of liver fibrosis. 
Key Words: Chronic liver disease. HBV, ALT, 
Liver fibrosis,Biopsy 
 
Introduction 
There are about 350 to 400 million people who are 
infected with chronic hepatitis B worldwide.1 The 
clinical course is marked by a wide range from 
asymptomatic carrier state to cirrhosis, hepatic 
decompensation and hepatocellular carcinoma1. In 
Pakistan, chronic Hepatitis B is a major problem and 
has intermediate Hepatitis B prevalence with a carrier 
rate of 4 to 5 %. 2 
Although high risk is attributed in patients who are 
HBsAg positive of developing sequel of disease but of 
these only minimal numbers of patients develop 
cirrhosis and hepatocellular carcinoma.3 Recent 
development in techniques of genome detection has 
shifted the focus from serological studies to HBV 
detection for diagnosis and management. 
Liver biopsy, which is the investigation of choice for 
inflammation and fibrosis, is strongly recommended in 
patients with persistent HBV DNA levels 2000 IU/ml 
and ALT 1 to 2 times the upper limit of normal.1, 4 Few 
histological studies have demonstrated that HBV DNA 
levels 2000 IU/ml and upper limit of ALT to 90 U/L 
for women and 30 U/L for men are associated with 
high likelihood of severe fibrosis. 
One of such study is REVEAL HBV study that showed 
that histological grades were significantly associated 
with serum HBV viral load.5 A study showed 
sensitivity of 50% and specificity of 79.6 % of ALT >40 
and HBV DNA more than or equal to 2000 IU/ml in 
predicting fibrosis and prevalence of 0.53.6 
The latest EASL, AASLD, APASL and ASPA 
Guidelines recommend commencing of antiviral 
therapy in patients in whom significant fibrosis 
(i.e,METAVIR F2-F4) exists. These guidelines do not 
recommend Hepatitis B DNA and serum ALT to be 
used as a marker of underlying fibrosis. The liver 
biopsy is considered to be “gold standard” for 
diagnosis of fibrosis with sensitivity and specificity 
more than 90 %.7, 8  
 
Patients  and Methods 
This study was conducted on 132 patients presenting 
with Hepatitis B. This cross sectional study conducted 
at Gastroenterology and Hepatology Division of Holy 
Family Hospital, Rawalpindi in a period of six months 
(April to October, 2015)..The patients included in this 
study were Hep B s Ag positive (by ELISA) and of 18 
to 60 years of age. Patients who had Positive Hepatitis 
C status (by ELISA) or decompensated chronic liver 
disease or abnormal blood complete picture or 
deranged coagulation profile or were unfit for liver 
biopsy due to any reason were excluded from this 
study. 
Detailed history and physical examination was carried 
out in standardized protocol. Complete blood count, 
liver function tests, HBV DNA was done. The liver 
biopsy was done after informed consent. The samples 
of liver biopsy were preserved in normal saline and 
formalin and were sent to histopathology laboratory of 
Pathology department of same hospital. Samples of 
ALT and HBV DNA were sent in serum bottles. HBV 
DNA levels >2000 IU/ml and ALT> 90 U/L for 
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women and >30 U/L for men are predictor for liver 
fibrosis. All the data was recorded on a specially 
designed performa separately for each case. Data was 
analyzed in SPSS version 18. The diagnostic accuracy 
was calculated for serum HBV DNA and ALT levels 
using 2×2 table keeping liver biopsy as gold standard. 
 
Results 
Out of 132 patients, there were 72 (54.5%) males and 
60 (45.5%) females. The mean ± standard deviation age 
of study population was 43.78± 10.285 years. Results of 
HBV DNA + ALT showed 51(38%) patients to have 
fibrosis while it was absent in 81(62%), whereas 
endoscopic diagnosis of esophageal varices was 
confirmed in 40(30%) patients and absent in 
92(70%)(Table 1).Based on these results, while taking 
biopsy as the gold standard, the sensitivity of HBV 
DNA + ALT for diagnosis of fibrosis was found to be 
55%, specificity 66.6%, positive predictive value 43% 
and negative predictive value 78 % and diagnostic 
accuracy of 65% (Table 2) 
 
Table 1: HBV DNA + ALT  X Biopsy  diagnosis 
of fibrosis 
 Biopsy diagnosis of 
fibrosis 
Yes No 
HBV DNA + 
ALT 
Yes 22(16%) 29(22%) 
No 18(13%) 63(47%) 
 
Table 2: Diagnostic accuracy of HBV DNA 
with biopsy for diagnosis of fibrosis 
Sensitivity  55% 
Specificity 67% 
Positive predictive value 43.13% 
Negative predictive value 77.77% 
Diagnostic accuracy  65% 
 
 
Discussion 
In management of CHB patients, histological liver 
evaluation is an important part of the severity 
assessment and has importance for treatment 
decisions.9 Although liver biopsy is a gold standard to 
determine the stage of fibrosis and degree of 
necroinflammation, it is an invasive procedure with 
minimal but significant risk of morbidity and 
mortality.10 Therefore, many non-invasive methods 
have been applied to replace this invasive 
procedure.Similar results were seen in a study by 
Sanai et al .11 In addition, the positive predictive value 
was found to be 81% and negative predictive value 
91%. Another study showed that a serum HBV DNA 
would provide a theoretical sensitivity of 71.1%, with 
theoretical specificity of 73.4% in patients. 12 
There are three recognized phases of chronic hepatitis 
B infection: immune tolerant phase, immune clearance 
phase, and inactive or residual phase.13 During the 
immune clearance phase, HBV DNA level is greater 
than 2,000/ml or 20,000 IU/ml depend upon the HBe 
Ag negative or positive status of the patient.14 Acute 
flares of hepatitis activity with elevated levels of 
serum ALT may occur during this phase. Higher ALT 
levels, therefore, usually reflect the more vigorous 
immune response against HBV and more extensive 
hepatocytes damage.15On liver biopsy, nearly all of 
these patients have active hepatitis with variable 
degrees of fibrosis. All  patients should be considered 
candidates for treatment.This phase is eventually 
followed by HBe Ag seroconversion to its antibody 
(anti-HBe) and/or undetectable or low HBVDNA < 
2,000 IU/ml with normal ALT levels called inactive 
HBsAg carriers or low replicative phase.16 On liver 
biopsy, they have no evidence of inflammation and in 
most cases no fibrosis. As a result, there is no reason 
why these patients require treatment for HBV. 
Liver biopsy is most useful in these persons who do 
not meet clear cut guidelines for treatment.17 These are 
the patients who are greater than 40 years of age, with 
ALT greater than the upper limits of normal but less 
than 2 ULN, HBV DNA levels > 2000 but < 20,000, and 
other clinical features suggestive of chronic liver 
disease and concomitant diseases. In the presence of 
moderate to severe necroinflammation and/or at least 
moderate fibrosis on liver biopsy, treatment of 
hepatitis B is warranted.18 
One form of discordance is referred to as an immune 
tolerant phase.19 Patients in the immune tolerant phase 
are usually young, Hepatitis B e Antigen (HBeAg) 
seropositive with high viral loads > 20,000 IU/ml but 
normal serum alanine aminotransferase (ALT). A 
recent study has confirmed that patients in the 
immune-tolerant phase show minimal disease 
progression. However, HBeAg positive subjects older 
than 40 years with persistent 'high normal' ALT may 
have significant hepatic necroinflammation or 
fibrosis.20-21 Even with the current potent antiviral 
agents, it is difficult to completely suppress the high 
levels of HBV DNA found in these patients and 
treatment may significantly increase the risk of 
developing resistance over time. These patients should 
be kept under regular follow-up with ALT measured 
every 3 - 6 months. Performing a liver biopsy in these 
patients is often helpful to ensure that there is no on-
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going inflammation and to confirm that the patient is 
indeed in an 'immune-tolerant state. 22 
Conclusion 
Liver fibrosis prediction by measurement by HBV 
DNA + ALT can be considered as a simple non-
invasive method to identify patients with fibrosis.  
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